Home/ Supplements/ Niacin/ Niacin Sustained Release 500 mg

Niacin Sustained Release 500 mg

product on market Tablet or Pill PL Progressive Laboratories Safety: 60/100
60/100

Review before taking

  • Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · grounded in 1 source · methodology

Niacin is used to support cholesterol levels and cardiovascular health, with strong evidence supporting its lipid-lowering effects. However, the safety score indicates potential concerns, as high doses can cause flushing or liver enzyme elevations. This sustained-release formulation aims to mitigate some side effects while maintaining efficacy.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

AI-generated · Qwen 3.6 · grounded in 2 sources · methodology

This product received a low safety score because it contains 500mg of Niacin, which is over 14 times the recommended upper limit for daily intake.

Label

Product Label

Label for Niacin Sustained Release 500 mg
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
Vitamin
Product Type
100%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

500 mg (2500% DV)
Exceeds UL by 14.3× (UL: 35 mg) 196 studies (A:5, B:63)

Other Ingredients

Carnauba wax Vegetable Lubricant Croscarmellose Sodium
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Directions for Use

Directions: One tablet one to four times daily, or more, as directed by a doctor.

Warnings & Precautions

Tamper evident band around cap and seal on bottle. Do not use if either seal is broken or missing.

Keep out of reach of children.

Notice: Niacin may produce flushing, tingling, itching and feeling if warmth in certain individuals, which under normal continuous use will disappear. However, of conditions persist, consult a doctor.

Additional Information

Sold only for dispensing by a licensed health care professional.

This product has been packaged in a 3rd party inspected, GMP facility. (Good Manufacturing Practices)

Rev. E0213 Reorder No. 435

GMP 3rd party confirmed compliant

Science + Therapeutic potency = Results Since 1972

Formulated to release part of the niacin quickly, with the remainder being released over several hours.

Metadata

Product Details

UPC / SKU3 51821 00435 8
DSLD Entry Date2017-02-24
Product TypeVitamin
FormTablet or Pill
DSLD ID71252
Data Updated2026-04-11
Research

Research Evidence

241
Research Sources
55
Avg Quality
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013 PubMed DOI
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014 PubMed DOI
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024 PubMed DOI
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010 PubMed DOI
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010 PubMed DOI
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019 PubMed DOI
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016 PubMed DOI
View all evidence for Niacin →
Compare

Similar Products

View all Niacin products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.